Evaluation Reports of Dynamiker G and GXM Assay Get Approved on ECCMID

ECCMID is a yearly event that provides opportunity for the world’s leading experts and scholars come together and discuss the latest developments in infectious diseases, infection control and clinical microbiology.  On the 26th ECCMID conference, Peking Union Medical College Hospital published two clinical evaluation reports based on Dynamiker G and GXM assay, respectively.

One of the topic “Performance of Dynamiker® (1-3)-beta-D glucan assay compared to Fungitell® for the diagnosis of invasive fungal diseases from serum samples” reported clinical evaluation results by the comparison between Dynamiker Fungus (1-3)-beta-D glucan assay (G assay) and ACC Fungitell Assay. The total coincidence rate of two assays was 88.9%. The report was recommended to present as oral presentation and the number was 0141 which can be referred from the following website: http://eccmidlive.org/#resources/performance-of-dynamiker-1-3-beta-d-glucan-assay-compared-to-fungitell-for-the-diagnosis-of-invasive-fungal-diseases-from-serum-samples

Another topic was “Comparison of an enzyme-linked immunosorbent assay and a latex agglutination test of cryptococcal antigen test on cerebrospinal fluid and serum”, published a total coincidence rate of 93.9% from the comparison between Dynamiker Cryptococcus neoformans antigen assay and IMMY Cryptococcus latex agglutination test. The report further demonstrated that, by using cerebrospinal fluid (CSF) as samples, Dynamiker GXM assay exhibited more advantages than IMMY Cryptococcus latex agglutination test towards result identification and disease detection. This report was presented as poster presentation with a number of P1645 that can be found in the website below: http://eccmidlive.org/#resources/comparison-of-an-enzyme-linked-immunosorbent-assay-and-a-latex-agglutination-test-of-cryptococcal-antigen-test-on-cerebrospinal-fluid-and-serum

Dynamiker Biotechnology, in accordance to superior clinical evaluation results, has achieved wide concern and approval by users from home and abroad. As specialise in diagnosis of invasive fungal disease (IFD), Dynamiker will continue in exploration and innovation, ensure the high quality of products, and establish competitive edge in domestic and foreign markets with core technology.